具有双重5HT6对抗性/ HDAC6抑制作用的因特皮尔丁衍生物
Andreas Gkanas1, Maria Koutiva1, Theodora Katsila2
1Department of Chemistry, University of Patras, Rio Campus, Achaia, 26504, Greece.
Chemistry (Weinheim an der Bergstrasse, Germany)
|August 22, 2025
概括
研究人员开发了一种针对5-HT6受体和HDAC6酶的新型双重作用药物. 这种化合物在阿尔茨海默氏症等疾病中具有增强认知功能的潜力.
科学领域:
- 神经科学
- 医学化学
- 药理学
背景情况:
- 阿尔茨海默病 (AD) 和其他痴呆症显著影响生活质量,有效治疗方法有限.
- 目前的药物主要是治疗症状,而有针对性的疗法却在临床试验中失败.
- 通过解决多种生物机制,多目标联体为复杂的神经退行性疾病提供了有前途的策略.
研究的目的:
- 设计和合成针对5-HT6受体和HDAC6酶的新型双作用配体.
- 探索这些化合物的潜力作为认知增强剂.
- 开发一种神经退行性疾病的新疗法.
主要方法:
- 设计和合成双重的5-HT6抗剂/ HDAC6抑制剂,通过将酸药与因特皮尔丁结合.
- 开发了一种格拉姆级合成因特皮尔丁.
- 对合成的衍生物进行抑制功效和受体亲和的特征.
主要成果:
- 成功合成新的双作用5-HT6抗剂/ HDAC6抑制剂.
- 衍生物RG- 283AG对HDAC6具有微小分子功效 (IC50 = 0. 54μM) 和对5-HT6受体具有纳米分子亲和力 (Ki = 0. 7nM).
- RG-283AG具有良好的血脑屏障透能力.
结论:
- RG-283AG是首个报告的具有潜在认知增强功能的双重作用的5-HT6 / HDAC6配体.
- 这种双重向方法是开发阿尔茨海默氏症和其他痴呆症新疗法的有希望的策略.
- 需要进一步研究RG-283AG的治疗潜力.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
344
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
344
01:23Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
241
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
241
01:21Antipsychotic Drugs: Typical and Atypical Agents
314
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
314
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
400
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
400